Saw an announcement today they launched a multi-site clinical study to try and get some sales. I don't even have my fingers crossed; I'm feeling that a lottery ticket has a better chance of paying off.

I understand your point; I hope we see a real positive result from the $3.5 million. Not just more loss.

Is it possible this $3.5 million is not real?

There is not much left to say other than avoid those who "managed" this company.

April 9, 2020 - Gilbert, AZ - Rivulet Films’ Executives Aaron Klusman and Mike Witherill are announcing a merger with publicly traded Bio-Matrix Scientific Group, Inc. (“Bio-Matrix”) (ticker symbol BMSND), intending to rename Bio-Matrix as Rivulet Media.

Bio-Matrix Scientific Group as a medical development company has been an investor's nightmare. Now it's a media specialist? Come on guys, get real ....

It's looking like they are running a scam and are milking it for all they can get out of it. All those "expert testimonials" are on the payroll!

I'm with those who think ARTH management needs to demonstrate they can bring AC5 to market. This is needed without anymore delays. With FDA and CE approval in place the only remaining question is if ARTH management has what it takes to make this a success. Anyone investing big bucks in ARTH will certainly need to see this!

I'm back to hopeful but having difficulty staying positive ...

This progress is good but, at this point, we need solid news that marketing is beginning. We need news that there is a committed partner bringing AC5 onto the market. Hoping to see this soon, but have been waiting many years; I'm having difficulty believing management will get this done.

It would be nice to feel they are proceeding with some competence; for that they need to demonstrate they are making progress which has been totally lacking.

I'm with you guys hoping for some substantial news!

I found Arch Therapeutics on the website scheduled for January 13th at 4PM. To find this select the "Presenting Companies" tab then clicked on "2020 Presenting Companies". Then scrolled down the listing to find Arch Therapeutics. (ebdgroup.com/bts will get you thete)

Is there a problem manufacturing AC5 in large quantities? Anyone know if this is the problem?

This sets 0.22 share price ... and CE approval is still not here ... not very encouraging ...

Does anyone know if there is any progress in the US? Progress toward finally getting AC5 onto the market?

Where is ARTH management in pursuing approval in the US?

That's the question. Does his team have the ability to make this work? This has big potential but they have messed up big time over the past years. Can we believe/trust that they have gotten rid of the source of the problem. Do they have current negotiations in process that, for marketing issues, can't be announced yet? This feels like trust while standing on thin ice ...

Me too, hoping they do

Yes, nice to see a live body there. I read an earlier review about jnj having similar products on their shelf. I'm thinking that ARTH needs to find a pharmaceutical that wants to compete with jnj ....

It will be interesting to see how the price moves in the coming days. After so may disappointments during the past years it may take time for this news to settle in.

... don't bogart that joint, pass it around :)

I am feeling really good that I bought more shares today .... I certainly agree that there are other opportunities out there but today ARTH is my focus!

Really great news, very nice. Looks like having passed this milestone was worth waiting for. The ROTH article is dated December 11, 2018 and is worth reading. Any comments on ROTH itself will be appreciated. They projected, pending AC5 Topical's 510k approval, this:

"We assign ARTH shares a Buy rating and a $2.10/share price target. We arrive at our $2.10/share price target from a sum-of-the-parts analysis, with AC5 Topical valued at $1.25/share and AC5 Surgical valued at $0.85/share, with the rest of Arch’s earlier-stage pipeline remaining as upside to our current projections."

Nice analogy, it give a visual effect that describes the last few years. Hope this time it flies!

Hope so, June is close so I'm sitting tight ... somewhat nervously

My thought exactly, bad management can kill a good company. ARTH management is looking to much like that!

thanks, just trying to regain a positive perspective

why do you see an easy double?

Considering the CE and FDA mess up they should get paid nothing. But, with Norchi getting 510k where is the accountability? As a design engineer in corporate settings I have seen people fired for lesser mess ups.

Being up front with my position, I just sold all my shares. I just don't have any faith left that Norchi et al will get this moving any time soon. Probably never. During these past three years they have repeatedly messed up in nonsensical ways. While I will keep watching it I think it will most likely end in a painful demise for who ever hangs on. The only sure winners are those with the six figure salaries.

Let's get focused on whether Norchi and associates are really able to get AC5 through CE/510k/et al and onto market. Or are they just playing us all for suckers. Thus far they have demonstrated that they can't do this. I am phasing from being optimistic to disgust. They have been using the MIT connection to keep us. Does anyone know what the MIT held patent number is? Does arth really have exclusive marketing rights? I asked arth via email for the number but haven't heard anything back! I spoke with MIT and they said they take very seriously this stuff but need the patent number to look into it.

Hi GrosPied, I'm also very concerned. I've been with arth for over 3 years and am holding onto my shares for now. But, I'm very concern about Norchi's ability to get the FDA issues resolved. His staff, past and present, has a poor track record per CE and getting clinical trials completion. I really feel that Norchi needs to demonstrate in a very timely manor he can get AC5 moving. I think he is running out of time.

Do you think they can answer the FDA'S questions and get us moving forward, or is that wishful thinking?

Me too, sitting tight for a little longer. But Norchi needs to give us a reason to believe he can fix this.

I am holding lots of shares and want to see ARTH succeed. For that to happen management needs to get CE and clinical trials done, and get AC5 on the market. So far ARTH management has messed up both points. This causes me to have serious concerns that what we saw last year will be repeated next year, same people doing the same messing up. We need to see some solid progress. Does that mean new people are needed? Again, I am holding lots of shares and am feeling very let down by this series of mess ups!

I have been in ARTH for over 3 years and am hanging in for now. But I am feeling like that kitten hanging from a branch by its front paws. Pitiful. Concerned that a big pay day is slipping away while those responsible are banking big pay checks.

Norchi needs to fix this staff performance problem. If he doesn't then Dhillon needs to fix it. If they don't then there will be no 2019 for ARTH.

Your right, I am still up. At this time I'm hanging in for now, but would really like to see some of those 9/7 staff members leave the company for bad performance. That would be a positive sign for me. ARTH needs a staff that can get AC5 to market, the current staff has shown it just can't do that. They are ruining ARTH'S chances. As a software design engineer I would have been fired long ago if I missed my milestones this badly. Norchi and Dillons need to show some strength and fix this! If they don't then ARTH will be a failed company, and it will be their fault.

I've been in ARTH for three years and am troubled by this non-sensible mfg facility and CE submissions. Now, this problem with the 510k withdrawal saying they don't have the information to satisfy the FDA questions. What have those 9 senior management staff members been doing for all this time, anything useful? Are the resumes describing their qualifications accurate? Point is, if they are that qualified then why can't they get this stuff done correctly? More time will not help if they just don't have the needed skill set. Get rid of them and hire people who can get things done.

They have 9 senior management and 7 medical/scientific advisors and they couldn't get that correct! Is there anyone at ARTH that has the needed skill set to do this correctly. At this point they have shown that they do not have the correct skills for the job. They need to leave ARTH and be replaced with people with the correct skills for the tasks!